Edwards Lifesciences Corp Goodwill & Intangibles Disclosure
| United States | Europe | Rest of World | Total | ||||||||||||||||||||
Goodwill at December 31, 2023 | $ | 710.7 | $ | 58.2 | $ | 376.2 | $ | 1,145.1 | |||||||||||||||
Goodwill acquired during the year (Note 10) | 429.2 | — | 205.4 | 634.6 | |||||||||||||||||||
| Currency translation adjustment | — | (3.0) | — | (3.0) | |||||||||||||||||||
Goodwill at December 31, 2024 | 1,139.9 | 55.2 | 581.6 | 1,776.7 | |||||||||||||||||||
Adjustments to goodwill from acquisition (Note 10) (a) | (15.1) | — | — | (15.1) | |||||||||||||||||||
| Currency translation adjustment | — | 7.0 | — | 7.0 | |||||||||||||||||||
Goodwill at December 31, 2025 | $ | 1,124.8 | $ | 62.2 | $ | 581.6 | $ | 1,768.6 | |||||||||||||||
| December 31, | |||||||||||||||||||||||||||||||||||||||||
| Weighted-Average Useful Life (in years) | 2025 | 2024 | |||||||||||||||||||||||||||||||||||||||
| Cost | Accumulated Amortization | Net Carrying Value | Cost | Accumulated Amortization | Net Carrying Value | ||||||||||||||||||||||||||||||||||||
| Finite-lived intangible assets | |||||||||||||||||||||||||||||||||||||||||
| Patents | 10.2 | $ | 53.0 | $ | (8.6) | $ | 44.4 | $ | 138.8 | $ | (90.5) | $ | 48.3 | ||||||||||||||||||||||||||||
| Developed technology | 14.4 | 617.8 | (44.5) | 573.3 | 665.2 | (47.4) | 617.8 | ||||||||||||||||||||||||||||||||||
| Other | 0.0 | 0.5 | (0.5) | — | 3.4 | (3.4) | — | ||||||||||||||||||||||||||||||||||
| 14.1 | 671.3 | (53.6) | 617.7 | 807.4 | (141.3) | 666.1 | |||||||||||||||||||||||||||||||||||
| Indefinite-lived intangible assets | |||||||||||||||||||||||||||||||||||||||||
| In-process research and development | 510.5 | — | 510.5 | 510.5 | — | 510.5 | |||||||||||||||||||||||||||||||||||
| $ | 1,181.8 | $ | (53.6) | $ | 1,128.2 | $ | 1,317.9 | $ | (141.3) | $ | 1,176.6 | ||||||||||||||||||||||||||||||
| 2026 | $ | 17.3 | |||
| 2027 | 27.7 | ||||
| 2028 | 48.8 | ||||
| 2029 | 69.7 | ||||
| 2030 | 88.0 | ||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 25, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
| 2023 | Feb 12, 2024 | |
| 2022 | Feb 13, 2023 | |
| 2021 | Feb 14, 2022 | |
| 2020 | Feb 12, 2021 | |
| 2019 | Feb 14, 2020 | |
| 2018 | Feb 15, 2019 | |
| 2017 | Feb 16, 2018 | |
| 2016 | Feb 17, 2017 | |
| 2015 | Feb 19, 2016 | |
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.